Novo to sell Wegovy subscriptions on Hims (NVO:NYSE)

Novo Nordisk (NVO) on Tuesday announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) available on telehealth platforms, including LifeMD (LFMD) and Hims & Hers (HIMS). As part of the program, cash-paying patients can choose 3-, 6-, or 12-month subscriptions ...